BioCentury | May 13, 2020
Product Development

Arvinas unveils first efficacy signal for targeted protein degradation, points to opportunity in resistant cancers

Arvinas’ top-line ASCO data provides the first evidence that targeted protein degraders can benefit patients, in particular those whose tumors have become resistant to standard therapies. Founded by targeted degradation pioneer Craig Crews in 2013,...
BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

High-wattage takeouts and commercial launches have revived interest in radiopharmaceuticals for cancer. The challenge for the new wave of candidates is to achieve enough differentiation to justify the logistical hurdles of manufacturing and delivering products...
BioCentury | May 20, 2019
Distillery Techniques

RB1 alterations predict survival in mCRPC patients treated with Zytiga or Xtandi

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Gene profiling Alterations in RB1 could help predict survival in mCRPC patients treated with Zytiga or Xtandi. In 429 patients with mCRPC, analysis of whole-exome sequencing, gene expression, histopathology, survival and...
BioCentury | Mar 1, 2019
Product Development

Prostate cancer disrupted

Two imminent disruptions threaten to upend the treatment landscape for prostate cancer, changing who gets anti-androgen therapies and ushering in the first new MOAs in decades. The launch of generic abiraterone means next generation anti-androgens...
BioCentury | Feb 6, 2019
Distillery Therapeutics

Cancer

INDICATION: Prostate cancer In vitro and mouse studies identified a chromenecarbaldehyde-based IRE1 inhibitor that could help treat prostate cancer. Optimization and in vitro binding assays of a family of tool compound IRE1 inhibitors yielded a...
BioCentury | Dec 8, 2018
Regulation

Path to opioid-free pain relief

To jump-start development of analgesics that can help stem the opioid crisis, companies want FDA’s upcoming guidelines to reduce uncertainty around outcomes that constitute clinically meaningful opioid sparing. But while an advisory panel put some...
BioCentury | Dec 4, 2018
Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture and mouse studies suggest inhibiting Hsp70 could help treat prostate cancer resistant to Xtandi enzalutamide and/or Zytiga abiraterone acetate. In human prostate cancer cell lines, high Hsp70 levels were associated...
BioCentury | Nov 2, 2018
Company News

J&J appeals district court decision invalidating Zytiga patent

Johnson & Johnson (NYSE:JNJ) on Oct. 31 filed to appeal a district court decision that will permit generic versions of prostate cancer drug Zytiga abiraterone acetate to launch after Oct. 31, according to company spokesperson...
BioCentury | Sep 14, 2018
Emerging Company Profile

Laekna’s jumping off place

Chinese biotech Laekna Therapeutics Shanghai Co. Ltd. is jump-starting its pipeline with a trio of clinical cancer compounds from Novartis AG. The safety of the lead candidate and its potential to synergize with the other...
BioCentury | Aug 10, 2018
Clinical News

Strongbridge's Cushing syndrome candidate meets in Phase III

...2S,4R-enantiomer of ketoconazole, an inhibitor of cytochrome P450 family 11 subfamily B polypeptide 1 (CYP11B1), CYP17A1...
...subfamily B polypeptide 1 (CYP11B1); CYP17A1; CYP21A2 Description: 2S,4R-enantiomer of ketoconazole, an inhibitor of CYP11B1, CYP17A1...
...1Q19) Chris Lieu Recorlev, levoketoconazole (COR-003, COR003, NormoCort) Strongbridge Biopharma plc Cytochrome P450 family 11 subfamily B polypeptide 1 (CYP11B1) Cytochrome P450 family 17 subfamily A polypeptide 1 (CYP17A1) Cytochrome...
Items per page:
1 - 10 of 187